To meet rising demand for highly potent active pharmaceutical ingredients (APIs) spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Switzerland-based CARBOGEN AMCIS AG today announced that it has completed a capital investment project to upgrade its high potency capabilities. An industry leader in the production of high potency APIs, CARBOGEN AMCIS offers drug developers the full range of high potency services, from development, manufacturing and chromatography, to antibody drug conjugates (ADCs), fill & finish, lyophilization, and life-cycle management.
The enhancements will include:
“The expansions in India and Switzerland continue CARBOGEN AMCIS’ investment in building out a global, high potency platform to meet the growing demand for high potency APIs for oncology applications. This move, along with parallel investments in the ADC arena in France and Switzerland, is a reflection of CARBOGEN AMCIS’ continued commitment to providing a broad range of personalized, expert services, capabilities and geographic choices to our clients to help them develop the next-generation cancer treatments,” commented Mark C. Griffiths, CEO, CARBOGEN AMCIS and the Dishman Group.
Choosing the right outsourcing partner for the development and manufacture of high potency APIs is a critical consideration for pharmaceutical companies who seek partners with expertise in chemistry, cutting-edge containment engineering technology and risk reduction in the handling of highly potent cytotoxic drugs. Since 2003, high potency APIs have been a core specialization for CARBOGEN AMCIS and the recent investments underscore the company’s commitment to offering strong technical expertise in the development and commercialization of New Chemical Entities (NCEs) and APIs, which resulted in the launch of more than 12 commercial products worldwide.
Thanks to its state-of-the-art R&D and manufacturing infrastructure and expertise in high potency APIs, CARBOGEN AMCIS is well positioned to contribute to the development of next-generation cancer treatments and other therapies.
About CARBOGEN AMCIS High Potency Facilities:
The Bubendorf facility was opened in 1987 and has seen a number of additions in its more than 20-year history. The manufacturing building was commissioned in 1996 and the lab, administration and containment facilities were opened in 2005. The site now supports over 180 employees, who focus on process optimization and supply of late-phase and commercial API supplies.
The Bavla facility complements the Bubendorf high potency facility. The plant is one of the largest, extensive and flexible custom-manufacture high potency facilities in the world and enables customers to work with CARBOGEN AMCIS from early-stage route development to market supply without volume limitations. The Bavla facility caters to both cytotoxic and non-cytotoxic highly active substances in dedicated areas.
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is a member of the Dishman Group based in Ahmedabad, India.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.
Source: CARBOGEN AMCIS AG, Bubendorf, Switzerland